Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03581188




Registration number
NCT03581188
Ethics application status
Date submitted
18/06/2018
Date registered
10/07/2018
Date last updated
1/08/2023

Titles & IDs
Public title
Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma.
Scientific title
A Randomised Controlled Pilot Trial of Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma.
Secondary ID [1] 0 0
ACTRN12616001716459
Secondary ID [2] 0 0
ANZMTG 02.17
Universal Trial Number (UTN)
Trial acronym
MEL-SELF
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Melanoma (Skin) 0 0
Condition category
Condition code
Cancer 0 0 0 0
Malignant melanoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Patient-led surveillance
BEHAVIORAL - Clinician-led surveillance

Experimental: Patient-led surveillance - Participants receive a mobile dermatoscope that attaches to their smartphone to take photos of skin lesions for teledermatology, instructions on skin self-examination from the ASICA skin checker App, text and email reminders to perform self-examination every 2 months, an educational booklet 'Your guide to early melanoma', and scheduled visits to their clinician as required.

Active comparator: Clinician-led surveillance - Participants receive an educational booklet 'Your guide to early melanoma' and scheduled visits to their clinician as required.


Treatment: Devices: Patient-led surveillance
Usual care plus reminders, ASICA instructional videos, a mobile dermatoscope, an app that facilitates store-and-forward teledermatology, and fast-tracked unscheduled clinic visits.

BEHAVIORAL: Clinician-led surveillance
Usual care (scheduled clinician visits)
Intervention code [1] 0 0
Treatment: Devices
Intervention code [2] 0 0
BEHAVIORAL
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The Percentage of Eligible and Contacted Patients Who Were Randomised Into the Trial
Timepoint [1] 0 0
Baseline
Secondary outcome [1] 0 0
Adherence to Recommended Total Body Skin Self Examinations Practice: Frequency of Skin Self-examinations.
Timepoint [1] 0 0
Baseline, at 6 months
Secondary outcome [2] 0 0
Adherence to Recommended Total Body Skin Self Examinations Practice: Thoroughness of Skin Self-examination
Timepoint [2] 0 0
Baseline, 6 months
Secondary outcome [3] 0 0
Successful Submission of Dermoscopic Images for Teledermatology (Intervention Group Only)
Timepoint [3] 0 0
At 6 months
Secondary outcome [4] 0 0
Number of Skin Clinic Visits Attended (Scheduled and Unscheduled)
Timepoint [4] 0 0
During the 12 months after randomisation
Secondary outcome [5] 0 0
Number of Skin Lesions Surgically Excised
Timepoint [5] 0 0
During the 12 months after randomisation
Secondary outcome [6] 0 0
New Subsequent Primary or Recurrent Melanoma Diagnoses
Timepoint [6] 0 0
12 months
Secondary outcome [7] 0 0
New Melanoma Diagnoses Prompted by Visit Type
Timepoint [7] 0 0
During 12 months after randomisation
Secondary outcome [8] 0 0
General Anxiety, Stress, and Depression Measured Using the Depression Anxiety Stress Scales-21
Timepoint [8] 0 0
Baseline, 6 months

Eligibility
Key inclusion criteria
* Patients treated for stage 0/I/II melanoma and are attending regular melanoma follow-up as indicated by scheduled visit within next 12 months in clinic patient booking system and
* Are able to self-examine;
* Have a suitable study partner (spouse, partner, family member, friend);
* Have a smart phone with access to Wifi / email / SMS text messaging;
* Are able to give informed consent ;
* Have sufficient English language skills to read the materials and complete the questionnaires;
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Unable to perform self-examination
* No partner or friend to help with self-examination
* Do not have access to a smart phone with Wifi/email/SMS text messaging
* With a known past or current diagnosis of cognitive impairment

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
17/02/2020
Sample size
Target
Accrual to date
Final
100
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Newcastle Skin Check - Newcastle
Recruitment hospital [2] 0 0
Melanoma Institute Australia - North Sydney
Recruitment hospital [3] 0 0
Royal Prince Alfred Hospital - Sydney
Recruitment postcode(s) [1] 0 0
2290 - Newcastle
Recruitment postcode(s) [2] 0 0
2060 - North Sydney
Recruitment postcode(s) [3] 0 0
2050 - Sydney

Funding & Sponsors
Primary sponsor type
Other
Name
University of Sydney
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Melanoma and Skin Cancer Trials Limited
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this pilot study is to evaluate digitally supported skin self-examination compared to usual care in people treated for localised melanoma.
Trial website
https://clinicaltrials.gov/study/NCT03581188
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Katy Bell, A/Prof
Address 0 0
University of Sydney
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03581188